Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity

被引：21

作者：

Ono, Akira ^{[1
]}

Murakami, Haruyasu ^{[1
]}

Serizawa, Masakuni ^{[2
]}

Wakuda, Kazushige ^{[1
]}

Kenmotsu, Hirotsugu ^{[1
]}

Naito, Tateaki ^{[1
]}

Taira, Tetsuhiko ^{[1
]}

Koh, Yasuhiro ^{[2
,3
]}

Ohde, Yasuhisa ^{[4
]}

Nakajima, Takashi ^{[5
]}

Endo, Masahiro ^{[6
]}

Takahashi, Toshiaki ^{[1
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[2] Shizuoka Canc Ctr, Res Inst, Drug Discovery & Dev Div, Shizuoka, Japan

[3] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan

[4] Shizuoka Canc Ctr, Div Thorac Surg, Shizuoka, Japan

[5] Shizuoka Canc Ctr, Div Diagnost Pathol, Shizuoka, Japan

[6] Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka, Japan

来源：

LUNG CANCER | 2016年 / 99卷

关键词：

Inflammatory myofibroblastic tumor; ALK; ASP3026; Ceritinib; NF1; Hyaluronan; RECEPTOR TYROSINE KINASE; CELL LUNG-CANCER; CERITINIB; CRIZOTINIB; RESISTANCE; SURVIVAL; ASP3026; SARCOMA;

D O I：

10.1016/j.lungcan.2016.07.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A 57-year-old male current smoker was diagnosed with an aggressive variant of ALK-rearranged inflammatory myofibroblastic tumor (IMT) arising in the pleural cavity. First line treatment with ASP3026 was initiated at a dose of 125 mg once daily. A follow-up CT scan revealed drastic regression of the pleural lesion. After disease progression with ASP3026 treatment, LDK378 (ceritinib) was initiated at a dose of 750 mg once daily. A follow-up CT scan revealed a second drastic regression of the pleural lesion. Furthermore, it is noteworthy that this case represents the use of serum hyaluronan levels to assist in monitoring of treatment efficacy in an IMT. Herein, we present the first case of a patient with a highly aggressive ALK-rearranged IMT arising in the pleural cavity, who showed both initial and subsequent drastic response to two ALK inhibitors while being monitored for serum hyaluronan. (C) 2016 The Author(s). Published by Elsevier Ireland Ltd.

引用

页码：151 / 154

页数：4

共 21 条

[1] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor [J].

Butrynski, James E. ;

D'Adamo, David R. ;

Hornick, Jason L. ;

Dal Cin, Paola ;

Antonescu, Cristina R. ;

Jhanwar, Suresh C. ;

Ladanyi, Marc ;

Capelletti, Marzia ;

Rodig, Scott J. ;

Ramaiya, Nikhil ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Wilner, Keith D. ;

Christensen, James G. ;

Jaenne, Pasi A. ;

Maki, Robert G. ;

Demetri, George D. ;

Shapiro, Geoffrey I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1727-1733

[2]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[3] Inflammatory pseudotumors of the lung [J].

Cerfolio, RJ ;

Allen, MS ;

Nascimento, AG ;

Deschamps, C ;

Trastek, VF ;

Miller, DL ;

Pairolero, PC .

ANNALS OF THORACIC SURGERY, 1999, 67 (04) :933-936

[4] EXTRAPULMONARY INFLAMMATORY MYOFIBROBLASTIC TUMOR (INFLAMMATORY PSEUDOTUMOR) - A CLINICOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF 84 CASES [J].

COFFIN, CM ;

WATTERSON, J ;

PRIEST, JR ;

DEHNER, LP .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (08) :859-872

[5] The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer [J].

Friboulet, Luc ;

Li, Nanxin ;

Katayama, Ryohei ;

Lee, Christian C. ;

Gainor, Justin F. ;

Crystal, Adam S. ;

Michellys, Pierre-Yves ;

Awad, Mark M. ;

Yanagitani, Noriko ;

Kim, Sungjoon ;

Pferdekamper, AnneMarie C. ;

Li, Jie ;

Kasibhatla, Shailaja ;

Sun, Frank ;

Sun, Xiuying ;

Hua, Su ;

McNamara, Peter ;

Mahmood, Sidra ;

Lockerman, Elizabeth L. ;

Fujita, Naoya ;

Nishio, Makoto ;

Harris, Jennifer L. ;

Shaw, Alice T. ;

Engelman, Jeffrey A. .

CANCER DISCOVERY, 2014, 4 (06) :662-673

[6] Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib [J].

Gainor, Justin F. ;

Tan, Daniel S. W. ;

De Pas, Tomasso ;

Solomon, Benjamin J. ;

Ahmad, Aziah ;

Lazzari, Chiara ;

de Marinis, Filippo ;

Spitaleri, Gianluca ;

Schultz, Katherine ;

Friboulet, Luc ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

CLINICAL CANCER RESEARCH, 2015, 21 (12) :2745-2752

[7] Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology [J].

Hallberg, Bengt ;

Palmer, Ruth H. .

NATURE REVIEWS CANCER, 2013, 13 (10) :685-700

[8] Novel ALK inhibitors in clinical use and development [J].

Iragavarapu, Chaitanya ;

Mustafa, Milaim ;

Akinleye, Akintunde ;

Furqan, Muhammad ;

Mittal, Varun ;

Cang, Shundong ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8

[9] An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor [J].

Jacob, Sanjivini V. ;

Reith, John D. ;

Kojima, Angerika Y. ;

Williams, William D. ;

Liu, Chen ;

Duckworth, Lizette Vila .

CASE REPORTS IN PATHOLOGY, 2014, 2014

[10] FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer [J].

Khozin, Sean ;

Blumenthal, Gideon M. ;

Zhang, Lijun ;

Tang, Shenghui ;

Brower, Margaret ;

Fox, Emily ;

Helms, Whitney ;

Leong, Ruby ;

Song, Pengfei ;

Pan, Yuzhuo ;

Liu, Qi ;

Zhao, Ping ;

Zhao, Hong ;

Lu, Donghao ;

Tang, Zhe ;

Al Hakim, Ali ;

Boyd, Karen ;

Keegan, Patricia ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2015, 21 (11) :2436-2439

← 1 2 3 →